Canceropôle Provence-Alpes-Côte d’Azur

What Canceropôle Provence-Alpes-Côte d’Azur does

Canceropôle Provence-Alpes-Côte d'Azur (also branded Canceropôle PACA or Canceropôle Sud) is a Groupement d'intérêt public (GIP) founded in 2003 and headquartered in Marseille, France. It functions as the regional coordination and funding platform for cancer research across the Provence-Alpes-Côte d'Azur region, one of seven Canceropôles that together form the national network recognised by INCa (Institut National du Cancer). The organisation connects academic researchers, clinicians, hospitals, and industrial actors, coordinating more than 650 active researchers and 50+ partner institutions, and operating as a public-interest entity rather than a commercial venture.

Its core activities comprise open calls for projects (notably the Masters Partagés programme), shared access to advanced technology platforms (proteomics, metabolomics, imaging, organoids, including assets such as the Orbitrap-Astral mass spectrometer and SARRP irradiator), structuring actions that pool equipment and protocols across sites (CEEVEC, Met'Connect, PETRA Network, ProteoPACA, MICA), technology transfer and valorisation services, and an entrepreneurship track (OncoSTART Entrepreneurship School, CNRS Innovation masterclasses). The organisation also runs a Cellule Europe supporting regional participation in Horizon Europe and EU Mission Cancer, and convenes the regional oncology community through an annual seminar (13th edition in 2026), monthly seminar series, and thematic workshops.

Canceropôle PACA does not sell products or services commercially; its activities are funded through institutional public subsidies from INCa and Région Sud (notably within the €40M Plan Cancer Régional 2022-2027) and partner foundations such as Fondation ARC. Its business model is therefore a coordination-and-grant-disbursement model: it aggregates public cancer research funding, deploys it through competitive calls and structuring actions, and retains a small secretariat (1-10 staff) that operates at the Timone campus (historically) and the CISAM health innovation campus (since January 2022). Strategic direction is set by a dual presidency — Norbert Vey (Institut Paoli-Calmettes, oncology) and Maureen Clerc (INRIA Sophia Antipolis, AI) — appointed in November 2025 to explicitly align cancerology and artificial intelligence in the regional research agenda.

Name

Canceropôle Provence-Alpes-Côte d’Azur

Legal name

Canceropôle Provence-Alpes-Côte d'Azur

Website

https://canceropole-paca.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Canceropôle Provence-Alpes-Côte d'Azur is a French public-interest grouping that coordinates and funds cancer research across the PACA region, channelling public subsidies into project calls, shared technology platforms, structuring actions, and entrepreneurship programmes for 650+ regional researchers and 50+ partner institutions.

Ownership category

akta.pro rank

Product category

Cancer Research Coordination and Funding

NAICS

Voluntary Health Organizations (813212), Grantmaking Foundations (813211), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Health Research Funding Agencies (Public/Quasi-Public) (HLAJALAB)

akta.pro secondary industries

Health & Medical Research Grantmaking Foundations (BPAGAKAL), Research Administration & Grants Management Support (Pre/Post-Award, Compliance) (EDAEALAO), Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

• Cancer research coordination
• Research funding programs
• Oncology innovation support
• Technology transfer services
• Research infrastructure access

Headquarters

HQ city

Marseille

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Distribution channels4 records

Marketing channels5 records

Core offering

Canceropôle PACA coordinates and funds cancer research across the Provence-Alpes-Côte d'Azur region through open calls for projects, shared technology platforms, structuring actions (CEEVEC, Met'Connect, PETRA Network, ProteoPACA), innovation valorisation, and entrepreneurship training. It aggregates public funding from INCa and Région Sud and channels it to over 650 researchers and 50+ partner institutions via programs such as Masters Partagés and the OncoSTART Entrepreneurship School.

Product overview

Canceropôle Provence-Alpes-Côte d'Azur is a regional cancer research and innovation cluster structured as a public interest group (GIP) that operates as a coordination and support platform rather than a single product company. The organization provides an integrated ecosystem of services including funding programs (Masters Partagés, project financing), research infrastructure support (Actions Structurantes, technological platforms), technology transfer (Valorisation des Découvertes), professional development (OncoSTART Entrepreneurship School), and communication tools (Newsletter). These services work together to support cancer researchers, clinicians, and entrepreneurs across the Provence-Alpes-Côte d'Azur region in advancing cancer research and bringing innovations to clinical application.

Differentiator

Problem solved

Functional benefit

Products and services

• Masters Partagés A shared master's degree funding program that supports training and education in cancer research for students and young researchers in the Provence-Alpes-Côte d'Azur region.
• Actions Structurantes Structural research support programs including CEEVEC, Met'Connect, PETRA Network, ProteoPACA, and MICA that strengthen regional cancer research infrastructure and capabilities.
• Financement de Projets Project financing services providing grants and financial support for cancer research initiatives and innovation projects in the regional ecosystem.
• Valorisation des Découvertes Discovery valorization services helping researchers transfer their scientific findings into commercial applications and clinical practice.
• Plateformes Technologiques Access to advanced technological platforms and expertise supporting cancer research, including proteomics, imaging, organoids, and other specialised facilities.
• OncoSTART Entrepreneurship School Entrepreneurship training program for oncology innovators, helping participants develop business models and accelerate their cancer-focused entrepreneurial projects.
• Séminaire Annuel Annual seminar event bringing together the regional cancer research community for knowledge sharing, poster presentations, and scientific exchange.

Quantifiable outcome

• Over €20M invested in regional research since 2003
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Partnerships

14 partnerships are on record, tiered core, major and supporting.

• Norbert Vey and Maureen Clerc (Presidency)coreOthers · 1 November 2025Norbert Vey (President of Institut Paoli-Calmettes) and Maureen Clerc (INRIA Sophia Antipolis) were appointed as co-presidents of Canceropôle PACA in November 2025, uniting cancerology and artificial intelligence in the organisation's governance.
• Fondation ARC pour la recherche sur le cancercoreStrategic or Co-development Partner · 29 November 2023Fondation ARC renewed its 3-year partnership with Canceropôle PACA in November 2023, focused on supporting young researchers and strengthening interactions between cancer research teams. Initial partnership began in 2020. Joint press release and coverage in multiple outlets.
• INRIA (Institut National de Recherche en Informatique et en Automatique)coreStrategic or Co-development Partner · 3 February 2022INRIA joined Canceropôle PACA as a strategic partner in February 2022, bringing AI and digital health expertise to the cancer research ecosystem. Coverage in WebtimeMedias and La Tribune PACA (Feb 2022) highlighted the alliance as 'l'IA contre le cancer'. The partnership was formalised through a press release by Canceropôle and INRIA Côte d'Azur.
• CISAM (Campus Innovation Santé Aix-Marseille)majorStrategic or Co-development Partner · 11 January 2022Partnership agreement signed in January 2022 with CISAM, making it the new headquarters location for Canceropôle PACA, as reported by Made in Marseille (Jan 2022). The CISAM facility houses the Canceropôle's operational offices, co-locating the organisation within a health innovation campus.
• Ligue 06 (Ligue contre le cancer – Alpes-Maritimes)supportingGTM or Marketing Partner · 27 May 2021Canceropôle and Ligue 06 signed a partnership convention in May 2021 to strengthen collaboration in the Alpes-Maritimes territory, supporting regional cancer research activities and patient engagement.
• Inserm TransfertcoreStrategic or Co-development Partner · 10 December 2020Canceropôle PACA and Inserm Transfert signed a partnership agreement in December 2020 to strengthen collaboration in oncology, covering technology transfer, valorisation, and joint support for researchers. The partnership was renewed in May 2024. Press coverage in La Provence, Le Quotidien du Médecin, and AEF Info.
• ATLAS Programme PartnerscoreStrategic or Co-development Partner · 30 September 2020The ATLAS programme (launched September 2020) is a multi-partner public-private consortium uniting Canceropôle PACA, academic institutions, and private companies to advance lymphoma research. Coverage in La Tribune PACA (Nov 2020) and Businews described it as an open-innovation model for lymphoma treatment development.
• EurobiomedmajorStrategic or Co-development Partner · 5 March 2019Eurobiomed (competitiveness cluster for health technologies) and Canceropôle PACA signed a partnership in March 2019. They co-organise events such as European Opportunities workshops and oncology/immunology sessions, and collaborate on matchmaking between researchers and industry.
• SATT Sud Est (Société d'Accélération de Transfert de Technologies)supportingTechnology or Integration · 14 September 2018Partnership with SATT Sud Est (technology transfer company) since September 2018, aimed at accelerating the transfer of cancer research discoveries to commercial applications and supporting oncology spin-offs.
• CNRS InnovationsupportingStrategic or Co-development PartnerCNRS Innovation co-organises masterclasses on health start-up creation with Canceropôle Sud. A masterclass held in March 2026 featured Dr Maeva Dufies (co-founder of Roca Therapeutics, a CNRS deeptech spin-off) sharing her entrepreneurship experience with the regional community.
• OncoSTART ConsortiumsupportingStrategic or Co-development PartnerThe OncoSTART consortium (including Canceropôle Sud) organises the OncoSTART Entrepreneurship School — a week-long oncology entrepreneurship training programme held at Paris Saclay Cancer Cluster. Canceropôle Sud funds registrations for professionals and students.
• Unicancer PACAmajorStrategic or Co-development PartnerUnicancer PACA (representing Centre Antoine-Lacassagne, Institut du Cancer Avignon-Provence, and Institut Paoli-Calmettes) co-organises regional oncology events with Canceropôle PACA, including the 3rd Regional Day of Oncology in October 2026 in Avignon.
• ARTC Sud (Association pour la Recherche sur les Tumeurs Cérébrales)supportingGTM or Marketing PartnerARTC Sud partners with Canceropôle PACA and AP-HM for events such as the annual 'Mai en Gris' brain tumour awareness month and the 6th Caregivers Day at Hôpital de la Timone, supporting patient engagement and public outreach.
• Plateforme Qualité de Vie et Cancer / CEReSSsupportingStrategic or Co-development PartnerThe Quality of Life and Cancer Platform (supported by Canceropôle PACA) and CEReSS co-organise scientific workshops on patient-reported outcomes and AI-driven patient-centred measurement in oncology, demonstrating collaboration on patient quality of life research.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Eurobiomed: Competitiveness cluster for health technologies in the same PACA + Occitanie region, formally partnered with Canceropôle PACA since 2019. Co-organises European Opportunities and oncology matchmaking events; comparable as a regional life-sciences coordination/funding body.
• Canceropôle CLARA (Lyon Auvergne-Rhône-Alpes): Canceropôle for the Auvergne-Rhône-Alpes region with identical GIP-style coordination and funding mandate. Comparable in scale and structure, focused on immunooncology, haematology and precision medicine.
• Canceropôle Île-de-France: Largest of the seven French Canceropôles, coordinating oncology research across the Paris region with the same GIP-like coordination/funding model. Most directly comparable peer given identical mandate, structure and funder ecosystem (INCa + regional authority).
• Canceropôle Grand Est: Eastern France Canceropôle with the same GIP-style coordination mandate, covering Grand Est region. Comparable in scope and structure to Canceropôle PACA.
• Canceropôle Sud-Ouest: South-Western France Canceropôle with the same national coordination role. Often co-organises events with Canceropôle PACA (e.g. drug development training Sept 2026), evidencing structural comparability.
• Canceropôle Nord-Ouest: North-Western France Canceropôle (Hauts-de-France + Normandie). One of the seven national Canceropôles with the same mandate, funding model and coordination role.
• Canceropôle Grand Ouest: Western France Canceropôle coordinating cancer research across Brittany, Pays de la Loire and Normandy. Directly comparable as one of the seven national Canceropôles with the same public coordination role.

Others

• Institut Paoli-Calmettes: Leading French Comprehensive Cancer Centre in Marseille and partner institution whose president (Norbert Vey) now co-leads Canceropôle PACA. Represents the clinical delivery counterpart that Canceropôle PACA helps coordinate research around.
• Inserm Transfert: French national technology-transfer subsidiary of Inserm, partnered with Canceropôle PACA since 2020 (renewed 2024). Comparable as an adjacent enabling organisation in the French cancer research funding and valorisation ecosystem.

Emerging players

• Paris-Saclay Cancer Cluster: Newer oncology-focused cluster on the Paris-Saclay plateau, aiming to become a leading European oncology innovation hub. Overlaps with Canceropôle PACA's mission but with a stronger industry-led spin-off focus and concentrated AI/digital health ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canceropôle Provence-Alpes-Côte d’Azur